EGFR and neoplasm: In addition, Grunewald et al. [54] used decitabine in combination with EGFR and CD44V6-specific CAR T cells for anti-BCa studies (Fig. 2G), finding that the combination was an attractive therapeutic approach to enhance tumor-specific killing in BCa.